DeciBio’s Post

If you have been following solid tumor MRD at all over the past few years, you know just how quickly the landscape is changing. The is a constant stream of new reimbursement decisions, product launches, and partnerships, all of which are driving how (and how much) biopharma and clinical stakeholders are utilizing the tools. We interviewed 10 oncologists and decision-makers in the biopharmaceutical industry to discuss trends in adoption over the last six months, considerations in evaluating vendors, and near-term expectations for utilization. The report is available on our website: https://lnkd.in/gXfhdTRZ. Please reach out if you would like to discuss! #MRD #precisionmedicine #liquidbiopsy Check out Natera, Guardant Health, Personalis, Inc., NeoGenomics Laboratories, Invitae, Foundation Medicine, and more

Pharma companies can help patients access biomarker testing by providing resources on patient identification, available vendors, proof of eligibility, and ordering instructions. MMIT and The Dedham Group share tips for oncology manufacturers in Drug Channels: https://ow.ly/Vj2U30sFK4I. #Pharma #PharmaManufacturers #MarketAccess #Oncology

Will you attend Swiss Biotech Day 2024 In Basel? Join our panel of "ADCs and Beyond" on Monday, April 22th. With the approval of trastuzumab deruxtecan (Enhertu) in 2019, we have been witnessing the soaring numbers of both preclinical and clinical ADC assets as well as a number of eye-catching investments and licensing deals in this field. What could be the development strategies for the next generation of ADCs? What are the potentials on other bioconjugates other than typical ADCs (i.e. XDC)? Can the therapeutic areas be expanded beyond oncology? Join our panel of varied industry experts and explore these topics. Find out more about the event: https://lnkd.in/dfseDhjc #swissbiotechday #swissbiotechday2024 #ADC #Bioconjugate #ADCdisocvery #ADCdevelopment #ADCmanufacturing #CDMO

Meanwhile in Europe, Navigo is proud to be the Innovation Partner at the 5th Targeted Radiopharmaceutical Summit, Berlin #TRP EU At Navigo we are solving two main challenges for targeted radioligand therapy (#RLT): target-specific delivery and optimal biodistribution, using our toolbox of target specific Affilins® and half-life optimizing HEAD® technology. Don’t miss the presentation by our CSO Ulrich Haupts tomorrow (7th Dec) showcasing the novel Affilin® Radiotheranostics with best-in-class potential and unprecedented modularity for fast innovation. #precisiontargeting for #precisionmedicine #oncology #innovation

@Catailyst Trending Topics Incyte to Present Late-Breaking Phase 3 Results for #Retifanlimab (Zynyz®) and Initial Data from Phase 1 #CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024 https://lnkd.in/e-dTVEhQ Versant Ventures and Novartis Launch Borealis Biosciences, Inc. With $150 Million in Funding https://lnkd.in/eXP8bb29 Bayer Initiates #Phase II Study of Soluble Guanylate Cyclase Activator (BAY3283142) in Patients With #Chronic #Kidney #Disease https://lnkd.in/eXVVr_43 Tris Pharma Initiates ALLEVIATE-1 and ALLEVIATE-2, Pivotal Phase 3 #Trials Investigating Cebranopadol, a First-in-Class Compound with a Novel Mechanism of Action to Treat #Pain https://lnkd.in/eg2_Rvkp

BioPharmCatalyst's Weekly Watchlist for August 12th, 2024: Exciting updates ahead! MeiraGTX Holdings (NASDAQ: MGTX) and IO Biotech (NASDAQ: IOBT) are gearing up for significant milestones in the coming months. MeiraGTX Holdings is on track to unveil data from its Phase 3 trial of bota-vec, targeting improvements in retinal sensitivity and vision for XLRP patients by 3Q 2024. Meanwhile, IO Biotech's top candidate, IO102-IO103 in conjunction with Keytruda, targets melanoma and is poised for an overall response rate readout during the same period. Stay informed on these and other key phase 3 catalysts set for the quarter by visiting the article below. Don't miss out! Subscribe to our Weekly Watchlist via the website link provided. https://lnkd.in/eSsUi3C2 #biotech #biotechstocks #weeklywatchlist #fdacalendar #fasterscience #catalysts #pharma #biotechinvesting #oncology #drugpipeline

In this week's Weekly Watchlist, we focus on Phase 3 catalysts across indications for the next 6 months. Check out the link below! #phase3 #drugpipeline #fasterscience #biopharmcatalyst #fdacalendar #weeklywatchlist #biotech #biotechinvestor #biotechinvesting

📣 ICYMI📣 July's Resource Roundup includes: 📖 How to set up your CDMS/EDC to overcome staffing challenges and grow with you 📊 What other small biopharma orgs and CROs think about the latest eClinical trends 🏥 Meeting the regulatory push for Real-Time Oncology Review (RTOR) while executing mid-study changes Learn more here: https://bit.ly/3W2xbVT #EDC #CDMS #Oncology #Biotech #CRO #DataQuality #ClinicalDataManagement #ClinicalTrials

Will you attend Swiss Biotech Day 2024 In Basel? Join our panel of "ADCs and Beyond" on Monday, April 22th. With the approval of trastuzumab deruxtecan (Enhertu) in 2019, we have been witnessing the soaring numbers of both preclinical and clinical ADC assets as well as a number of eye-catching investments and licensing deals in this field. What could be the development strategies for the next generation of ADCs? What are the potentials on other bioconjugates other than typical ADCs (i.e. XDC)? Can the therapeutic areas be expanded beyond oncology? Join our panel of varied industry experts and explore those topics. Find out more about the event: https://lnkd.in/dfseDhjc #swissbiotechday #swissbiotechday2024 #ADC #Bioconjugate #ADCdisocvery #ADCdevelopment #ADCmanufacturing #CDMO

To effectively optimize drug dosage in early phase oncology, sponsors should plan for added operational load from increased data collection, assessments and strict turnaround time for assay work. In this Contract Pharma article, IQVIA Biotech’s VP of Immuno-Oncology & CAGT Erin Finot, MS, MBA discusses operational considerations for clinical trial stakeholders. Read the article to learn more. https://bit.ly/3X3qvIF #IQVIABiotech #clinicaltrials #oncology